Markets

Enanta Pharmaceuticals prices IPO at $14, the low end of the range

Enanta Pharmaceuticals, a biotech focused on developing small molecule drugs to use against hepatitis C, raised $56 million by offering 4.0 million shares at $14, the low end of the range of $14 to $16. Enanta Pharmaceuticals plans to list on the NASDAQ under the symbol ENTA. J.P. Morgan and Credit Suisse acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ENTA

Other Topics

IPOs

Latest Markets Videos

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More